Bank of America Forecasts Strong Price Appreciation for Hims & Hers Health (NYSE:HIMS) Stock

Posted by Geri Gentry on Jul 9th, 2026

Hims & Hers Health (NYSE:HIMS – Get Free Report) had its price target upped by stock analysts at Bank of America from $36.00 to $37.00 in a report released on Thursday,Benzinga reports. The firm presently has a “neutral” rating on the stock. Bank of America‘s target price would suggest a potential upside of 2.66% from the stock’s previous close.

Several other research firms have also issued reports on HIMS. JPMorgan Chase & Co. dropped their price target on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. TD Cowen decreased their price objective on shares of Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a research report on Friday, March 27th. Citigroup boosted their price objective on shares of Hims & Hers Health from $24.00 to $28.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 12th. Canaccord Genuity Group upped their target price on shares of Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Finally, Needham & Company LLC raised their target price on shares of Hims & Hers Health from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $30.70.

Check Out Our Latest Report on HIMS

Hims & Hers Health Stock Down 0.4%

HIMS stock opened at $36.04 on Thursday. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. The business has a 50 day moving average price of $29.05 and a two-hundred day moving average price of $26.34. The company has a market cap of $8.34 billion, a price-to-earnings ratio of -400.44, a P/E/G ratio of 101.79 and a beta of 2.35. Hims & Hers Health has a twelve month low of $13.74 and a twelve month high of $70.43.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The company had revenue of $608.10 million for the quarter, compared to the consensus estimate of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The company’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.20 EPS. Analysts anticipate that Hims & Hers Health will post 0.03 EPS for the current fiscal year.

Insider Activity at Hims & Hers Health

In related news, COO Michael Chi sold 14,027 shares of Hims & Hers Health stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total transaction of $441,850.50. Following the completion of the sale, the chief operating officer owned 432,124 shares of the company’s stock, valued at approximately $13,611,906. The trade was a 3.14% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Patrick Harrison Carroll sold 23,726 shares of the company’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $35.00, for a total transaction of $830,410.00. Following the completion of the transaction, the insider owned 181,861 shares in the company, valued at approximately $6,365,135. This trade represents a 11.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 167,161 shares of company stock worth $5,041,152 in the last quarter. 11.76% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently made changes to their positions in HIMS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Hims & Hers Health by 23.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock valued at $12,373,000 after purchasing an additional 78,543 shares during the period. Geneos Wealth Management Inc. acquired a new stake in shares of Hims & Hers Health during the first quarter worth $30,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Hims & Hers Health by 273.7% during the second quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock worth $47,000 after buying an additional 687 shares in the last quarter. Amundi boosted its position in shares of Hims & Hers Health by 5.3% in the second quarter. Amundi now owns 10,296 shares of the company’s stock valued at $489,000 after acquiring an additional 522 shares during the period. Finally, California Public Employees Retirement System grew its stake in shares of Hims & Hers Health by 9.5% in the second quarter. California Public Employees Retirement System now owns 338,620 shares of the company’s stock valued at $16,880,000 after acquiring an additional 29,471 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

(Get Free Report)

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.